Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Akebia Therapeutics Ownership Summary


Akebia Therapeutics is owned by 28.23% institutional investors, 2.09% insiders, and 69.67% retail investors. Blackrock is the largest institutional shareholder, holding 5.68% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.81% of its assets in Akebia Therapeutics shares.

AKBA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAkebia Therapeutics28.23%2.09%69.67%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock11.64M5.68%$11.87M
Vanguard group9.28M4.53%$9.46M
Alerce investment management5.75M2.80%$5.86M
Geode capital management4.54M2.21%$4.63M
Renaissance3.91M1.91%$3.99M
State street2.75M1.34%$2.80M
Jacobs levy equity management2.09M1.02%$2.14M
Qube research1.74M0.85%$1.78M
Connor, clark & lunn investment management1.05M0.51%$1.07M
Federated hermes865.25K0.42%$882.56K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alerce investment management5.75M11.49%$5.86M
Orchard capital management86.83K0.03%$88.56K
Wealth effects27.00K0.01%$27.54K
Eagle wealth strategies12.00K0.01%$12.24K
Jacobs levy equity management2.09M0.01%$2.14M
State of wyoming49.73K0.01%$50.72K
Cedrus13.70K0.01%$13.97K
Renaissance3.91M0.01%$3.99M
Compass ion advisors25.09K0.01%$45.92K
Virtu financial75.08K0.01%$77.00K

Top Buyers

HolderShares% AssetsChange
Blackrock11.64M0.00%9.10M
Geode capital management4.54M0.00%2.72M
State street2.75M0.00%2.10M
Vanguard group9.28M0.00%1.05M
Bank of new york mellon604.55K0.00%585.79K

Top Sellers

HolderShares% AssetsChange
Alerce investment management5.75M11.49%-7.46M
Acadian asset management---4.06M
Millennium management45.69K--3.22M
Goldman sachs group348.92K0.00%-1.06M
Qube research1.74M0.00%-518.06K

New Positions

HolderShares% AssetsChangeValue
Nuveen asset management380.54K0.00%380.54K$388.15K
Corebridge financial111.91K0.00%111.91K$115.27K
New york state common retirement fund101.10K0.00%101.10K$103.00K
Alliancebernstein77.64K-77.64K$79.19K
Voya investment management71.70K0.00%71.70K$73.13K

Sold Out

HolderChange
Hexagon capital partners-186.00
Headlands-208.00
Laurel wealth advisors-229.00
Redwood wealth management group-300.00
Capital advisors-320.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20241189.26%59,390,7035.52%283.74%599.26%268.33%
Jun 30, 2024108-14.29%56,234,084-1.41%273.04%53-27.40%24-
Mar 31, 202412638.46%57,038,6344.20%303.55%7397.30%2414.29%
Dec 31, 20239113.75%54,737,4217.65%293.92%3732.14%21-
Sep 30, 202380-3.61%50,849,4941.12%273.67%28-6.67%21-4.55%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv5.95M2.81%-
iShares Russell 2000 ETF5.53M2.63%-12.43K
Vanguard Institutional Extnd Mkt Idx Tr2.60M1.23%-
Fidelity Small Cap Index2.13M1.01%-40.14K
iShares Russell 2000 Value ETF1.78M0.84%-
Fidelity Extended Market Index1.12M0.53%23.02K
Vanguard Russell 2000 ETF948.40K0.45%-5.92K
State St Russell Sm/Mid Cp® Indx NL Cl C850.51K0.40%-42.80K
Federated Hermes MDT Small Cap Growth IS809.71K0.39%-
Federated Hermes MDT SCG Institutional809.71K0.39%-1.00

Recent Insider Transactions


DateNameRoleActivityValue
May 13, 2024Hadas Nicole R. SVP, Chief Legal OfficerSell$15.14K
May 13, 2024Dahan Michel SVP, Chief Operating OfficerSell$43.90K
Aug 25, 2023Burke Steven Keith SVP, Chief Medical OfficerSell$31.05K
Feb 29, 2024Dahan Michel SVP, Chief Operating OfficerSell$13.68K
Feb 29, 2024Hadas Nicole R. SVP, Chief Legal OfficerSell$9.44K

Insider Transactions Trends


DateBuySell
2024 Q2-2
2024 Q1-10
2023 Q3-1
2023 Q2-4
2023 Q1-19

AKBA Ownership FAQ


Who Owns Akebia Therapeutics?

Akebia Therapeutics shareholders are primarily institutional investors at 28.23%, followed by 2.09% insiders and 69.68% retail investors. The average institutional ownership in Akebia Therapeutics's industry, Biotech Stocks , is 47.04%, which Akebia Therapeutics falls below.

Who owns the most shares of Akebia Therapeutics?

Akebia Therapeutics’s largest shareholders are Blackrock (11.64M shares, 5.68%), Vanguard group (9.28M shares, 4.53%), and Alerce investment management (5.75M shares, 2.80%). Together, they hold 13.01% of Akebia Therapeutics’s total shares outstanding.

Does Blackrock own Akebia Therapeutics?

Yes, BlackRock owns 5.68% of Akebia Therapeutics, totaling 11.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.87M$. In the last quarter, BlackRock increased its holdings by 9.1M shares, a 358.35% change.

Who is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested?

Alerce investment management is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested, with 11.49% of its assets in 5.75M Akebia Therapeutics shares, valued at 5.86M$.

Who is the top mutual fund holder of Akebia Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Akebia Therapeutics shares, with 2.81% of its total shares outstanding invested in 5.95M Akebia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools